Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has recently announced a forthcoming change to its board of directors. Dagmar Rosa-Bjorkeson, who has been serving as a director since 2019, will not stand for reelection at the company's 2025 annual meeting of stockholders. This decision comes as she plans to pursue another business opportunity.
Bassil Dahiyat, Ph.D., President and CEO of Xencor, expressed gratitude for Rosa-Bjorkeson's contributions, particularly to the board and audit and nominating and governance committees. He highlighted her strategic guidance in advancing programs and rebalancing the company's portfolio.
Xencor is actively working to recruit additional board members with complementary skillsets to fill the impending vacancy.
In terms of financial developments, Xencor is currently a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. The company has more than 20 candidates engineered with its XMAB® technology in clinical development, with multiple XMAB medicines already being marketed by partners. The XMAB engineering technology allows for small changes to a protein's structure, resulting in new mechanisms of therapeutic action.
It's worth noting that Xencor's financial metrics and performance indicators have not been explicitly outlined in the press release. Following these announcements, the company's shares moved 1.8%, and are now trading at a price of $19.84. For the full picture, make sure to review Xencor's 8-K report.
